

2024 Taiwan Biotech Forum

Navigating the Next Generation
of Precision Medicine

San Diego, CA

June 2nd, 2024
Westin San Diego Gaslamp Quarter
910 BROADWAY CIRCLE, SAN DIEGO,
CALIFORNIA, USA, 92101

Welcome Message



Shiing-Jer Twu

**Chairman
Development Center for
Biotechnology (DCB)**

DCB is thrilled to be hosting the 2024 Taiwan Biotech Forum, a regular precursor to our annual participation in US BIO. This event fosters Taiwanese-US relations, and facilitates networking among medical centers and enterprises; all to drive technological R&D and industrial growth, and to further promote global collaboration in the industry. With the gracious support of the Department of Industrial Technology (DoIT) under the Ministry of Economic Affairs (MoEA), DCB spearheads industry advancements, leading Taiwanese biotech players into the North American market, and nurturing international connections and cooperation. This year's forum theme, "Navigating the Next Generation of Precision Medicine," underscores the vital role of precision medicine in healthcare, technology with the ability to revolutionize treatment through tailored approaches to diseases.

We are honored to have gathered esteemed experts and scholars from Taiwan and the United States. Together, we shall analyze the future trends of global precision medicine, and examine progressive material, such as artificial intelligence-assisted drug development, nucleic acid drugs, and cellular and gene therapy.

Beyond this forum, DCB will continue actively engage in matchmaking at US BIO, fostering technology transfer and R&D collaborations to elevate Taiwan's biotech globally. We eagerly anticipate partnering with international firms in the Asia-Pacific region. Thank you to all our guests for joining the 2024 Taiwan Biotech Forum; DCB wishes you success and fulfillment in your endeavors.

Table of Contents

<u>Agenda</u>	<u>3</u>
<u>Organizer</u>	<u>4</u>
<u>Sponsors</u>	<u>5</u>
<u>Speakers</u>	<u>6</u>
<u>Fireside Chat</u>	<u>10</u>
<u>Associates</u>	<u>15</u>

Agenda

1:30-2:00 PM	Registration	
2:00-2:10 PM	Welcome Remarks	Shiing-Jer Twu, MD, PhD Chairman, Development Center for Biotechnology
2:10-2:40 PM	Keynote Speech	Taby Ahsan, PhD Vice President, Cell Therapy Operations, City of Hope Moderator Yun Yen, MD, PhD Emeritus President and Chair Professor, Taipei Medical University
2:40-3:10 PM	Keynote Speech	Kyle Farh, MD, PhD Vice President of Artificial Intelligence, Illumina
3:10-3:25PM	Break & Networking	
3:25-4:25 PM	Panel Discussion	<p>Moderator: Tsai-Kun Li, PhD Vice President, Development Center for Biotechnology</p> <p>Panelists: Yun Yen, MD, PhD Emeritus President and Chair Professor, Taipei Medical University</p> <p>Taby Ahsan, PhD Vice President, Cell Therapy Operations, City of Hope</p> <p>Kyle Farh, MD, PhD VP & Distinguished Scientist, Illumina Inc</p> <p>M. Sherry Ku, PhD, RPh Founder and President of Kuder Consulting Company</p>
4:25-5:25 PM	Fireside Chat	
5:25-5:30 PM	Closing Remarks	Michael Huang, PhD Vice President, Development Center for Biotechnology

Organizer

Development Center for Biotechnology (DCB)



The Development Center for Biotechnology (DCB) was established as a nonprofit research institution in 1984 using funds provided by the public and private sectors. Currently located in the National Biotechnology Research Park, the DCB champions technological innovation, industrial development, and talent cultivation as its core values. We focus on preclinical development and translational medicine research, and play a vital role in drug commercialization to drive the development of the biotechnology industry in Taiwan.

DCB focuses on research and development (R&D) of novel drugs and treatment. We offer technology licensing services as well as integration services from commissioned research to business promotion, in addition to fostering international collaborations.

The DCB aims to become the "best partner" in the biotechnology industry. Through innovative R&D, business incubation, and business promotion, we utilize our cumulative capacity in drug R&D to align with international biotechnology and pharmaceutical development trends, thereby ensuring the quality of life and health of Taiwanese people.

Primary Sponsor

Department of Industrial Technology (DoIT)



The Department of Industrial Technology (DoIT) promotes the research and innovation of industrial technology in Taiwan. Through its Technology Development Programs (TDPs), DoIT leverages the resources of research institutes, industry and academia; develops advanced technologies with potential industrial applications, fosters the development of emerging industries, and promotes industrial innovation and transformation.

Event Sponsors

Accelerated Biosciences



Accelerated Biosciences is offering alternative ethically sourced GMP stem cells that are multi-functional, genetically stable, high expansion capacity, and immune-privileged: the human trophoblast derived stem cells (hTSC). We are actively translating our research into viable, life-changing treatments and products in partnerships with academia, biotech start-ups, global pharma, and CDMOs. We have a broad IP estate that ensures freedom to innovate for all of our partners.

ACRO Biomedical Co., Ltd.



ACRO Biomedical is committed to the R&D and production of natural collagen scaffolds as high-end medical devices to promote repair and regeneration of human tissues and organs. The platform supercritical CO₂ decellularization technology is able to create non-recombinant collagen scaffolds that can be used in various medical fields without the use of chemical cross-linking agents.



Speakers Moderator & Panelist



Yun Yen, MD, PhD

**Emeritus President and
Chair Professor
Taipei Medical University**

Dr. Yen received a MD from Taipei Medical College in 1982 and a PhD in Pathology and Cell Biology from Thomas Jefferson University in 1988.

Dr. Yen serves as an Adjunct Professor at Case Western Reserve University, and California Institute of Technology, as well as an Emeritus President at Taipei Medical University in Taiwan. Dr. Yen's prior experience includes service as the Allen and Lee Chao Endowed Chair in Developmental Cancer Therapeutics at the City of Hope Comprehensive Cancer Center from 2008 until 2014, Chair of the City of Hope's Molecular Pharmacology Department, Interim Chair at the City of Hope Medical Oncology, and Associate Director for Translational Research at the City of Hope Comprehensive Cancer Center from 2005 until 2014. Dr. Yen holds memberships or fellowships in numerous professional organizations, including National Academy of Inventors, Russian Academy of Engineering, and American Association for the Advancement of Science, and has published more than 343 peer-reviewed journal articles.



Speakers Guest Keynoter



Taby Ahsan, PhD

**Vice President,
Cell Therapy Operations
City of Hope, Duarte**

Taby Ahsan, PhD, is Vice President of Cell & Gene Therapy Operations at City of Hope. Dr. Ahsan has over 20 years of experience in both basic and translational studies in the fields of tissue engineering, regenerative medicine, and immunotherapy. Taby trained in Bioengineering at UPenn and UC-San Diego, followed by a postdoctoral fellowship at GA Tech. Her initial industry experience was at one of the earliest tissue engineering companies, Advanced Tissue Sciences in La Jolla, CA. She went on to join the faculty in the Biomedical Engineering Department at Tulane University, where her lab focused on studying biomechanical regulation of both pluripotent and adult stem cells. In 2017, Taby joined RoosterBio in her continued efforts to help drive forward the field of regenerative medicine, and spent three years leading their research and development efforts. She was also Head of Analytical Development and Characterization for Biologics Development in the Therapeutic Discovery Division at MD Anderson Cancer Center prior to joining City of Hope in January of 2022. Taby is Chair of the Cellular, Gene and Tissue Advisory Committee (CTGTAC) for the FDA.



Speakers Guest Keynoter



Kyle Kai-How Farh, MD, PhD

**Vice President &
Distinguished Scientist
Illumina Inc.**

Kyle Farh, MD, PhD, is VP & Distinguished Scientist has been at Illumina since 2015, and leads the Artificial Intelligence lab at Illumina. The AI lab has been responsible to a large extent for the adoption of deep learning in clinical variant interpretation, including the pioneering SpliceAI and PrimateAI-3D algorithms, two widely used AI tools for clinical interpretation of human genetic variants. He holds a BS in computer science from Rice University, and MD/PhD degrees from Harvard Medical School, and the Massachusetts Institute of Technology in molecular biology. He completed his internship and residency in pediatrics and clinical genetics at Boston Children's Hospital, and his postdoctoral fellowship with Mark Daly and Brad Bernstein at the Broad Institute.



Speakers Guest Panelist



M. Sherry Ku, PhD, RPh

**Founder and President
Kuder Consulting Company
Chief Executive Officer (CEO)
Savior Lifetech Corporation**

Founding President and Board Member of RuenHuei Biopharmaceutical Company

- Founding President/CSO of TWi Biotech/TWi Pharma (Anchen) with 6 High Barrier ANDA filings within 18 months. Simultaneously established a pipeline of 6 new drugs, including 3 biologicals.
- Head of Early pharmaceutical Development in Wyeth Research, USA (now Pfizer). Her responsibilities starts from discovery interface through clinical proof of concept.
- Oversees new drug development for over 170 new clinical leads, resulting in 85 original NME IND filings.
- Developed seven (9) commercial products including Suprax, Zosyn/Tazocin, Zebeta, Isovorin, Thioplex, Sonata, Tygacil, Bosulif,* and Neratinib* from preformulation through NDA and FDA PAI activities (except post merger*).
- Sherry is a graduate of National Taiwan University (BS) and The Ohio State University (PhD) in Pharmaceutics and Pharmaceutical Chemistry.
- She currently holds over 70 patents/invention disclosures, and has additional 62 Journal publications.
- She was the Vice Chair of NJ Pharmaceutical Discussion Group, and is the chair elect of AAPS Physical Pharmacy and Biopharmaceutical section.
- She sits on USP expert council, and consults for sFDA, tFDA, IPEC and various Quality Councils. She is a licensed Pharmacist.



Fireside Chat Guest Speaker



Yuta Lee, MBA

**Founder and
Chief Executive Officer (CEO)
Accelerated Biosciences**

安斯瑞德生物科技

Human stem cells have enormous potential for clinical applications. However, sourcing the appropriate stem cells remains a challenge – embryonic stem cells and adult stem cells each have its own issues and limitations. Accelerated Biosciences is offering alternative ethically sourced GMP stem cells that are multi-functional, genetically stable, high expansion capacity, and immune-privileged: the human trophoblast derived stem cells (hTSC).



**Accelerated
Biosciences**

We are actively translating our research into viable, life-changing treatments and products in partnerships with academia, biotech start-ups, global pharmas, and CDMOs. We have a broad IP estate that ensures freedom to innovate for all of our partners.



Fireside Chat Guest Speaker



Dar-Jen Hsieh, PhD

**Chairman and
Chief Executive Officer (CEO)
ACRO Biomedical Co., Ltd.**

亞果生醫股份有限公司

ACRO Biomedical is committed to the R&D and production of natural collagen scaffolds as high-end medical devices to promote repair and regeneration of human tissues and organs. The platform supercritical CO₂ decellularization technology is able to create non-recombinant collagen scaffolds that can be used in various medical fields without the use of chemical cross-linking agents. These scaffolds repair damaged tissue effectively, and provide a favorable

ACRO
Biomedical Co., Ltd.

environment without causing immune and allergic reactions. With 71 global patents and 50 licenses, including 3 recent TFDA Class III medical device certifications, ACRO is expanding in the global medical biomaterials market, reinforcing its position in the industry.



Fireside Chat Guest Speaker



Steve McCloskey

Founder and
Chief Executive Officer (CEO)
Nanome

Nanome is the ultimate interface for scientific discovery, starting with molecular data. Top R&D labs conduct cutting-edge research and make billion-dollar decisions in Nanome. But, Nanome isn't just for experts, it's also used by students and amateur scientists studying chemistry and biology. Anyone can build 3D molecules or simulate an entire protein made of hundreds of atoms,



all in one collaborative environment. Transform the way you learn, design, and communicate molecular structures with Nanome. Available on the new Meta Quest Pro.



Panel Moderator



Tsai-Kun Li, PhD

**Vice President
Development Center for
Biotechnology**

Education

PhD in Pharmacology from the Rutgers
University and University of Medicine and Dentistry of New Jersey, USA

Experience

- Professor, Dept. & Graduate Institute of Microbiology, National Taiwan University
- Deputy Vice President, Academic Affairs, National Taiwan University
- CEO, NTU Centers for Genome and Precision Medicine, National Taiwan University
- Distinguished Expert, Development Center for Biotechnology
- Advisory Committee Member, National Sun Yat-sen University
- Dean, International College Provisional Office, National Taiwan University
- Associate Dean, College of Medicine, National Taiwan University
- Director, Office for International Affairs, College of Medicine, National Taiwan University
- Board Member, VSENCE Co., Ltd.
- Professor, School of Integrative and Global Majors, University of Tsukuba



Closing Remarks



Michael Huang, PhD

**Vice President
Development Center for
Biotechnology**

Education

PhD, Chemical Engineering, University of Massachusetts, Amherst, MA, USA
BS/MS, Chemical Engineering, National Taiwan University, Taipei, Taiwan

Experience

- Director, Department of Botanicals, Medical and Pharmaceutical Industry Technology and Development Center, New Taipei City, Taiwan
- Chief Technology Officer, Smart Vision Co. Ltd., New Taipei City, Taiwan
- Group Leader-Principal Research Scientist, Pharmaceutical Development, Pfizer, NY, USA
- Group Leader-Principal Research Scientist, Pharmaceutical Development, Wyeth Research, NY, USA
- Assistant Professor, Department of Chemical, Biological, Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ, USA

Co-Organizer



GeneOnline

Our Mission is to provide the latest global biotech/pharma trends and developments including conducting exclusive KOL interviews, publishing industry news and innovative technology trends, and covering global conferences and events.

Associates



TiBIA

TiBIA, Taiwan Biomedical Innovation Association, was jointly established by a group of professionals from the fields of drug development, clinical trial research, precision medicine, and artificial intelligence applications, in hope to contribute to the biomedical development in Taiwan.



SoCAL TBA

SoCal TBA, a non-profit organization, thrives to bridge the industrial and academic talents in the US and Asia in bio-med fields.